{"disease":{"id":"ebola-virus-disease","name":"Ebola virus disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":6,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"atoltivimab","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inmazeb","generic_name":"ATOLTIVIMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Low affinity immunoglobulin gamma Fc region receptor III-A","drug_class":"","quality_score":59,"revenue":"76","mechanism":"Inmazeb works by binding to the Ebola virus, preventing it from interacting with host cells and thereby reducing the severity of the disease."},{"drug_id":"odesivimab","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inmazeb","generic_name":"ODESIVIMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Low affinity immunoglobulin gamma Fc region receptor III-A","drug_class":"","quality_score":55,"revenue":"76","mechanism":"Inmazeb works by binding to the Ebola virus, preventing it from interacting with host cells."},{"drug_id":"maftivimab","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inmazeb","generic_name":"MAFTIVIMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":"76","mechanism":"Inmazeb works by binding to and neutralizing the Ebola virus."},{"drug_id":"inmazeb","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Inmazeb","company_name":"ANRS, Emerging Infectious Diseases","drug_phase":"marketed","molecular_target":"Low affinity immunoglobulin gamma Fc region receptor III-A, Envelope glycoprotein","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"ansuvimab-zykl","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"EBANGA","generic_name":"ANSUVIMAB-ZYKL","company_name":"RIDGEBACK BIOTHERAPEUTICS","drug_phase":"marketed","molecular_target":"Envelope glycoprotein","drug_class":"","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"ansuvimab","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ebov Mab114","generic_name":"ANSUVIMAB","company_name":"Ridgeback Biotherapeutics","drug_phase":"marketed","molecular_target":"","drug_class":"Zaire Ebolavirus Glycoprotein-directed Antibody","quality_score":10,"revenue":null,"mechanism":"Ansuvimab works by binding to the Ebola virus glycoprotein, preventing the virus from entering host cells."}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04152486","title":"Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":20426,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT03098862","title":"PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response","phase":"","overall_status":"COMPLETED","enrollment_count":4830,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT02876328","title":"Partnership for Research on Ebola VACcinations","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4789,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT02431923","title":"Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up","phase":"","overall_status":"COMPLETED","enrollment_count":4043,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03072030","title":"International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false},{"nct_id":"NCT02509494","title":"Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1023,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT06093646","title":"Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"MRC/UVRI and LSHTM Uganda Research Unit","has_results":false},{"nct_id":"NCT04028349","title":"ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"MRC/UVRI and LSHTM Uganda Research Unit","has_results":false},{"nct_id":"NCT04409405","title":"Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola)","phase":"","overall_status":"COMPLETED","enrollment_count":787,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT04815174","title":"Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease","phase":"","overall_status":"COMPLETED","enrollment_count":711,"lead_sponsor_name":"Alliance for International Medical Action","has_results":false},{"nct_id":"NCT04186000","title":"Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":699,"lead_sponsor_name":"Universiteit Antwerpen","has_results":false},{"nct_id":"NCT03820739","title":"EBOVAC-Salone Extension","phase":"","overall_status":"COMPLETED","enrollment_count":653,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT03161366","title":"Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Epicentre","has_results":false},{"nct_id":"NCT04235361","title":"Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University of Stirling","has_results":false},{"nct_id":"NCT05494801","title":"Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III","phase":"","overall_status":"COMPLETED","enrollment_count":203,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03140774","title":"Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines","phase":"","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT06036602","title":"Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Albert B. Sabin Vaccine Institute","has_results":false},{"nct_id":"NCT05130398","title":"Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Centre de Recherche Médicale de Lambaréné","has_results":false},{"nct_id":"NCT03929757","title":"A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT04711356","title":"Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":true},{"nct_id":"NCT00374309","title":"Experimental Vaccine for Prevention of Ebola Virus Infection","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04906629","title":"INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"University of Geneva, Switzerland","has_results":false},{"nct_id":"NCT04250168","title":"Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response","phase":"","overall_status":"TERMINATED","enrollment_count":43,"lead_sponsor_name":"Institute of Tropical Medicine, Belgium","has_results":false},{"nct_id":"NCT02718469","title":"Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Auro Vaccines LLC","has_results":false},{"nct_id":"NCT02451891","title":"A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":38,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT05724472","title":"Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"International AIDS Vaccine Initiative","has_results":false},{"nct_id":"NCT04723602","title":"Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Albert B. Sabin Vaccine Institute","has_results":false},{"nct_id":"NCT02495246","title":"A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT06100913","title":"Immunology of Ebola Vaccine","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT05064956","title":"Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT04717830","title":"An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus Disease","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false},{"nct_id":"NCT00605514","title":"Ebola and Marburg Virus Vaccines","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03462004","title":"Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03576690","title":"R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT05067166","title":"Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Ridgeback Biotherapeutics, LP","has_results":false}],"total":35},"guidelines":[],"source":"Drug Landscape verified database"}